La catena delle opzioni mostra i dati chiave delle opzioni azionarie di FuboTV a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per FuboTV..

FuboTV (NYSE:FUBO) Azioni, Catena delle Opzioni

FUBOTV INC

FuboTV

FuboTV Inc is a sports-first, live TV streaming company offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. It offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality suited to their preferences. The company has one operating segment, the streaming business. Geographically, the company generates a majority of its revenue from the United States and also has a presence in other markets.

Brazil,,Rio,De,Janeiro,-,May,19,,2023:,In,This

Long Ideas

News

Markets

Media

Trading Ideas

ATEX

CABO

FUBO

L&#39;analisi dell&#39;RSI suggerisce che tre titoli potrebbero essere prossimi a un&#39;inversione di tendenza e offrire interessanti opportunità.

Rialzo imminente per queste 3 azioni del settore dei servizi di comunicazione?

Rolling,Meadows,,Illinois,,Usa,-,March,27,,2022:,Gallaghers,Sign

AMAT

L&#39;analista della CNBC indica le società su cui puntare. I consigli per un portafoglio di investimenti solido.

Jim Cramer svela le sue scelte vincenti: ecco i titoli da non perdere

Pre-Market Outlook

GETY

Un&#39;analisi dei titoli di mercato che mostrano segnali di crescita imminente, che rappresentano un&#39;opportunità interessante per investire.

Queste 3 azioni tecnologiche potrebbero esplodere questo trimestre

FuboTV Inc

FUBON FINCL HLDG CO ORD by Fubon Financial Holding Co. Ltd.

Fubon Financial Holdings Co Ltd

FUBON FINCL HL S/GDR 144A by Fubon Financial Holding Co. Ltd.

FUBON FINCL HLD S/GDR by Fubon Financial Holding Co. Ltd.

Chugai Pharmaceutical Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CHGCY#OTC">CHGCY</a>) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">oral obesity pill</a>, orforglipron.
Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) is a major shareholder of Chugai, a Japanese pharmaceutical company. The company&#8217;s optimism stems from growing evidence that modern weight-loss drugs can lead to significant muscle loss, an issue Chugai thinks it can help address.
Hitoshi Iikura, a senior executive at Chugai, <a target="_blank" href="https://www.ft.com/content/4fd1fd94-0b70-48fb-861b-3bad6286ebae" rel="noreferrer noopener">told</a> the Financial Times the company has &#8220;high expectations&#8221; for combining GYM329, initially developed for spinal muscular atrophy (SMA), with orforglipron or similar therapies.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45769020/mounjaro-maker-eli-lilly-taps-swedish-firm-camurus-to-target-long-acting-obesity-market-in-870-million-deal" rel="noreferrer noopener">Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal</a>
Orforglipron, which Lilly licensed from Chugai, showed strong late-stage trial results, matching the safety and efficacy of popular injectables like Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy and Ozempic and Lilly&#8217;s Zepbound and Mounjaro.
The drug significantly <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44934811/eli-lilly-positioned-to-dominate-obesity-market-with-oral-option-analyst-initiates-with-confidence" rel="noreferrer noopener">reduced weight and blood sugar levels</a> and is expected to hit the market next year.
Chugai began developing orforglipron in 2003 as part of an effort to enhance diabetes treatments, aiming to make them longer-acting and tablet-based. Although obesity wasn&#8217;t an initial target, the company saw broader potential as research evolved. &#8220;We didn&#8217;t anticipate it but it&#8217;s ballooning,&#8221; Iikura said, referring to the unexpectedly large obesity market.
Studies suggest that 25% to 39% of weight loss from obesity drugs may be due to lean mass reduction, which includes muscle. Chugai argues that maintaining muscle mass is vital, especially for aging populations, and its GYM329 drug could be a key component in preventing this loss during weight-loss treatment.
Despite Chugai&#8217;s success, Roche had previously passed on orforglipron due to setbacks with an earlier weight-loss drug. At the time, much of the pharmaceutical industry was hesitant to enter the obesity space, except companies like Lilly and Novo Nordisk with strong metabolic disease portfolios.
However, with market interest and scientific breakthroughs accelerating, Roche reversed course in 2023 and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40422774/roche-misses-out-on-weight-loss-blockbuster-drug-now-playing-catch-up-in-booming-market" rel="noreferrer noopener">reentered the field</a>.
Meanwhile, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-06-07/lilly-s-obesity-drug-sales-rise-60-in-india-amid-rising-demand" rel="noreferrer noopener">reported</a> that Eli Lilly saw a 60% jump in sales of its weight-loss and diabetes drug Mounjaro in India in May compared to April, marking its second full month on the Indian market.
India has the third-largest obese population in the world.
According to market research firm Pharmarack Technologies, the U.S. drugmaker made 126 million rupees ($1.5 million) from Mounjaro injections last month.
Sales of the 5 mg dose more than doubled to 75 million rupees, while the 2.5 mg version brought in 51 million rupees.
According to the Indian Council of Medical Research (ICMR), there are 101 million people with diabetes in India. Of these, at least 40 million are on medication.
Vishal Manchanda, SVP of institutional research at Systematix Group,&nbsp;told&nbsp;Livemint that even if 0.5% of 40 million use Mounjaro, it would fetch Eli Lilly sales of <a target="_blank" href="https://www.benzinga.com/25/04/44824190/eli-lillys-mounjaro-launch-triggers-weight-loss-craze-in-india-novo-nordisk-seeks-to-move-up-wegovy-launch" rel="noreferrer noopener">$1.5 billion annually</a>.
Novo Nordisk&nbsp;is also trying to move up the launch of Wegovy in India to better compete with Lilly.
Price Action: LLY stock closed up 0.55% at $769.88 on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45814068/novo-nordisks-wegovy-tied-to-increased-risk-of-rare-vision-loss-disorder-european-regulators-say" target="_blank" rel="noreferrer noopener">Novo Nordisk&#8217;s Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

General

CHGCY

RHHBY

Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy

Buybacks

Viemed Healthcare Board Authorized Share Repurchase Program Up To ~1.98M Common Shares Through June 2026

Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda&#xAE;&nbsp;(pembrolizumab) as first-line treatment for advanced and metastatic Merkel cell carcinoma (MCC), conducted under Special Protocol Assessment (SPA) Agreement with U.S. Food and Drug Administration (FDA), later in June 2025
Resolution of partial clinical hold unlocks second tranche of funds from $12.5 million PIPE financing announced on June 3, 2025
TAMPA, Fla., June 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that the FDA has removed the manufacturing-related partial clinical hold on the Company's Phase 3 accelerated approval trial for IFx-2.0, thereby allowing the trial to proceed as agreed to under the previously announced SPA Agreement with the FDA.

HURA

FDA Removes Manufacturing-Related Partial Clinical Hold On TuHURA's Phase 3 Accelerated Approval Trial For IFx-2.0, Allowing Trial To Proceed As Agreed To Under Previously Announced SPA Agreement With FDA

Viemed Healthcare Announces Share Repurchase Program Of 1,976,441 Shares

Legal

GPUS

Hyperscale Data Enters Into Settlement Agreement With Gresham Worldwide's Senior Secured Noteholders For Chapter 11 Proceedings

PMGC Holdings Signe Letter Of Intent To Acquire Profitable U.S.-Based Electronics Manufacturing Company

Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe
Webinar to be held Tuesday, June 17, 2025, 12:00 PM ET
PRINCETON, N.J., June 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that it will host a virtual key opinion leader (KOL) event featuring Kevin Harrington, MBBS, PhD (The Institute of Cancer Research, United Kingdom) and Katharine A. Price, MD (Head and Neck Disease Group, Mayo Clinic Comprehensive Cancer Center), to discuss the unmet need and current treatment landscape for recurrent/metastatic HPV16-positive (head and neck squamous cell carcinoma) HNSCC.
The event will review the changing landscape of HNSCC in context with Merck's KEYNOTE-689 (KN-689) study and the rapidly increasing incidences of HPV16-positive HNSCC in the US and Europe. The event will also include a review of Versamune&#xAE; HPV, which is currently being evaluated in a Phase 3 clinical trial in combination with pembrolizumab as a first-line treatment for R/M HPV16+ HNSCC, as well as in Phase 2 clinical trials for the treatment of various types of HPV16-positive cancers. Versamune&#xAE; HPV is a novel investigational human papilloma virus (HPV)-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers. The panel will discuss the emerging treatment landscape in 1L R/M HNSCC and the view of HPV-positive and HPV-negative HNSCC as two distinct diseases with different underlying causes, pathology, and contributions to the development of HNSCC, as well as identification and treatment of HPV16+ HNSCC.
The event will be moderated by Kirk Shepard, M.D., PDS Biotech's Chief Medical Officer. A live question and answer session will follow the formal presentations.

PDSB

PDS Biotechnology To Host Virtual KO) Event To Discuss Unmet Need And Current Treatment Landscape For Recurrent/Metastatic HPV16-Positive HNSCC

<h3>Gainers</h3>
<ul>
<li>EpicQuest Education Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEIQ#NASDAQ">EEIQ</a>) stock rose 12.8% to $0.61 during Monday's pre-market session. The market value of their outstanding shares is at $8.0 million. </li>
<li>VinFast Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) shares rose 11.69% to $3.82. The company's market cap stands at $8.9 billion. As per the news, the Q1 earnings report came out today. </li>
<li>PLBY Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) shares moved upwards by 10.04% to $1.75. The company's market cap stands at $164.3 million. </li>
<li>Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) shares increased by 9.99% to $2.75. The market value of their outstanding shares is at $6.9 million. </li>
<li>Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) shares increased by 9.2% to $1.78. The market value of their outstanding shares is at $189.6 million. </li>
<li>JX Luxventure Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JXG#NASDAQ">JXG</a>) stock moved upwards by 8.57% to $2.66. The company's market cap stands at $10.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Children's Place (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) shares decreased by 21.1% to $5.41 during Monday's pre-market session. The market value of their outstanding shares is at $119.2 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Springview Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) stock declined by 7.63% to $0.47. The market value of their outstanding shares is at $5.4 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) stock fell 6.54% to $2.29. The company's market cap stands at $7.0 million. </li>
<li>Linkage Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCB#NASDAQ">LGCB</a>) shares fell 6.23% to $2.26. The market value of their outstanding shares is at $5.8 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) stock declined by 5.98% to $39.0. The market value of their outstanding shares is at $27.2 million. </li>
<li>Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) stock fell 5.3% to $1.79. The market value of their outstanding shares is at $4.2 million. As per the press release, Q1 earnings came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CHGG

EEIQ

LGCB

PLBY

PLCE

RIME

SBET

SPHL

XELB

12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

Canaccord Genuity analyst Joseph Vafi initiates coverage on Etoro Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETOR#NASDAQ">ETOR</a>) with a Buy rating and announces Price Target of $78.

Price Target

Initiation

Analyst Ratings

ETOR

Canaccord Genuity Initiates Coverage On Etoro Group with Buy Rating, Announces Price Target of $78

<h3>Gainers</h3>
<ul>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares rose 142.0% to $0.5 during Monday's pre-market session. The market value of their outstanding shares is at $16.1 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares moved upwards by 103.2% to $3.17. The market value of their outstanding shares is at $23.7 million. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) stock increased by 30.37% to $10.75. The company's market cap stands at $39.5 million. </li>
<li>Metsera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) stock increased by 16.4% to $32.0. The company's market cap stands at $3.3 billion. </li>
<li>Jade Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) stock moved upwards by 14.32% to $8.22. The company's market cap stands at $432.3 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares increased by 12.71% to $6.47. The market value of their outstanding shares is at $24.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Kalaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLRS#NASDAQ">KLRS</a>) shares declined by 23.9% to $2.51 during Monday's pre-market session. The company's market cap stands at $46.9 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares declined by 15.28% to $20.52. The company's market cap stands at $533.8 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock decreased by 13.77% to $0.94. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares fell 13.55% to $0.5. The market value of their outstanding shares is at $3.6 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock declined by 9.91% to $0.17. The market value of their outstanding shares is at $11.2 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) stock declined by 8.28% to $0.72. The company's market cap stands at $56.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLRX

CLSD

GLYC

HSDT

JBIO

KLRS

KLTO

LIMN

MTSR

SILO

Tempest Therapeutics, Inc. - Common Stock

TPST

12 Health Care Stocks Moving In Monday's Pre-Market Session

<ul>
<li>Motorcar Parts of America expects net sales for the fiscal year ending March 31, 2026 to be between $780 million to $800 million, representing between 3.0 percent and 5.6 percent year-over-year growth.</li>
<li>Operating income is expected to be between $86 million and $91 million, representing between 4.3 percent and 10.4 percent year-over-year growth.&nbsp;</li>
<li>The company estimates depreciation and amortization will be approximately $11 million.&nbsp;</li>
<li>These estimates do not include certain non-cash items and one-time expenses and exclude the impact of tariffs recently enacted due to the uncertainty and continuing changes.</li>
</ul>

Guidance

MPAA

Motorcar Parts of America Sees FY2026 Sales $780M-$800M Vs. Consensus Of $800M

BitMine Immersion Technologies, Inc. ("BitMine" and the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>), a technology company focused on the accumulation of Bitcoin for long-term investment, whether acquired by their Bitcoin mining operations or from the proceeds of capital raising transactions, today announced that it has made a purchase of 100 Bitcoin for its Bitcoin Treasury business line. The Bitcoin were purchased from funds from BitMine's recent offering of shares of common stock, which closed on Friday, June 6, 2025.

BMNR

BitMine Immersion Technologies Purchases 100 Bitcoin For Bitcoin Treasury Business Line

<h3>Gainers</h3>
<ul>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) stock rose 20.3% to $0.31 during Monday's pre-market session. The company's market cap stands at $17.3 million. </li>
<li>AgEagle Aerial Sys (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#AMEX">UAVS</a>) shares increased by 13.7% to $1.41. The company's market cap stands at $19.6 million. </li>
<li>Graham (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHM#NYSE">GHM</a>) stock rose 13.11% to $47.51. The market value of their outstanding shares is at $517.9 million. As per the news, the Q4 earnings report came out today. </li>
<li>Captivision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPT#NASDAQ">CAPT</a>) stock rose 12.65% to $1.38. The market value of their outstanding shares is at $45.0 million. </li>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) shares moved upwards by 12.42% to $5.35. The company's market cap stands at $11.9 million. </li>
<li>Hong Kong Pharma Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKPD#NASDAQ">HKPD</a>) shares increased by 12.22% to $2.02. The market value of their outstanding shares is at $22.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SOS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOS#NYSE">SOS</a>) stock fell 21.0% to $5.03 during Monday's pre-market session. The market value of their outstanding shares is at $15.2 million. </li>
<li>ZKH Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) shares decreased by 11.08% to $2.73. The company's market cap stands at $441.0 million. </li>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) stock fell 8.96% to $0.26. The company's market cap stands at $60.6 million. </li>
<li>Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) stock decreased by 7.93% to $1.16. The company's market cap stands at $114.1 million. </li>
<li>Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) shares declined by 7.49% to $0.54. The company's market cap stands at $17.7 million. </li>
<li>Linkers Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNKS#NASDAQ">LNKS</a>) stock decreased by 7.48% to $0.55. The company's market cap stands at $7.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAPT

HKPD

LNKS

LNZA

Nuveen Insured California Premium Fund Ii

OESX

UAVS

12 Industrials Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Diginex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) shares moved upwards by 17.2% to $73.85 during Monday's pre-market session. The company's market cap stands at $1.6 billion. </li>
<li>Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) stock moved upwards by 16.06% to $125.0. The company's market cap stands at $27.8 billion. </li>
<li>Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) stock increased by 15.9% to $9.4. The company's market cap stands at $65.9 million. </li>
<li>Unusual Machines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#AMEX">UMAC</a>) stock increased by 13.61% to $8.43. The company's market cap stands at $209.3 million. </li>
<li>Movano (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) shares rose 11.87% to $0.73. The market value of their outstanding shares is at $5.1 million. </li>
<li>Ondas Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) stock moved upwards by 11.76% to $1.9. The market value of their outstanding shares is at $261.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>VirnetX Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHC#NYSE">VHC</a>) shares decreased by 12.7% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $42.1 million. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) shares decreased by 10.18% to $0.32. The company's market cap stands at $9.0 million. </li>
<li>SmartKem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTK#NASDAQ">SMTK</a>) shares fell 9.6% to $1.21. The market value of their outstanding shares is at $5.3 million. </li>
<li>Mercurity Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) shares declined by 5.22% to $4.0. The market value of their outstanding shares is at $254.7 million. </li>
<li>FiEE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>) stock declined by 5.01% to $3.23. The market value of their outstanding shares is at $23.7 million. </li>
<li>VerifyMe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) shares fell 4.94% to $0.78. The market value of their outstanding shares is at $9.6 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALAR

CMBM

CRCL

DGNX

MINM

MOVE

ONDS

SMTK

UMAC

VRME

12 Information Technology Stocks Moving In Monday's Pre-Market Session

AstraZeneca Doses First Patient In DESTINY-Endometrial01 Phase 3 Trial Evlauating ENHERTU In Combination With Rilvegostomig Or Pembrolizumab Versus Platinum-Based Chemotherapy In Combination With Pembrolizumab As First-Line Therapy In Patients With HER2 Expressing Mismatch Repair Proficient Primary Advanced Or Recurrent Endometrial Cancer

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4444506-1&amp;h=2513402389&amp;u=https%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc.">Anixa Biosciences, Inc.</a>&nbsp;("Anixa" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and the principal investigator of the Phase 1 clinical trial of Anixa's ovarian cancer CAR-T immunotherapy, will present an e-poster at the European Society for Medical Oncology ("ESMO") Gynaecological Cancers Congress 2025, to be held on June 19-21, 2025 in Vienna, Austria.
Presentation Details:
<ul>
<li>Title: Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA)</li>
<li>Session Type: E-Poster</li>
<li>Poster No.: 145eTiP</li>
</ul>

ANIX

Anixa Biosciences To Present e-Poster On Ovarian Cancer CAR-T Clinical Trial At ESMO Gynaecological Cancers Congress 2025

Needham analyst John Todaro initiates coverage on Etoro Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETOR#NASDAQ">ETOR</a>) with a Buy rating and announces Price Target of $80.

Needham Initiates Coverage On Etoro Group with Buy Rating, Announces Price Target of $80

Earnings

Motorcar Parts of America Q4 2025 Adj. EPS $0.28 Beats $0.20 Estimate, Sales $193.10M Beat $190.70M Estimate

Logistic Properties of the Americas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) ("LPA" or the "Company") announced the execution of a new five-year U.S. dollar- denominated lease for 121,600 square feet of logistic space with a regional third-party logistics provider (3PL) at LPA Coyol 4 Logistic Park in San Jose, Costa Rica. This new agreement reflects approximately a 20% increase in the net effective rental rate, including common area maintenance fees, compared to the previous lease for the same space, which underscores the high demand and increasing value of institutional-grade logistics properties in Costa Rica.

Logistic Properties Of The Americas Executes 5-Yr U.S. Dollar- Denominated Lease For 121,600 Sqft Of Logistic Space With Regional 3PL At LPA Coyol 4 Logistic Park In San Jose, Costa Rica

Telsey Advisory Group analyst Dana Telsey maintains G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) with a Market Perform and lowers the price target from $30 to $27.

GIII

Telsey Advisory Group Maintains Market Perform on G-III Apparel Group, Lowers Price Target to $27

Press Releases

Fubo Closed 2024 With Record $1.59B Revenue, 1.676M Paid Subscribers in North America

Fubo to Stream Texas Rangers Baseball Through New Carriage, Sponsorship Agreement With Rangers Sports Network

Fubo to Announce Q1 2025 Financial Results on May 2, 2025

Fubo Announces Inducement Grants Under NYSE Listing Rule 303A.08

Fubo Retains Exclusive Rights to Premier League in Canada With Multi-Year Agreement Beginning With 2025/2026 Season

Fubo's Global Streaming Business Exceeded Subscriber Guidance, Achieved Revenue Targets in Q1 2025

Fubo Brings Live European League of Football to Fubo Sports Fast Network With Multi-Year Agreement

Fubo Launches First to Market Programmatic Pause Ads on CTV

Fubo, DAZN Strike Multi-Year Integrated Partnership

Fubo Expands Live Sports Streaming Options With Pay-Per-View

Angi

Autohome Inc. American Depositary Shares, each representing four class A ordinary shares.

Autohome

Bumble

Cars.com

Trump Media & Technology Group Corp. - Warrants

Trump Media & Tech Gr

EverQuote

Getty Images Holdings, Inc. Class A Common Stock

Getty Images Holdings

GIBO Holdings Limited - Class A Ordinary Shares

GIBO Holdings

JOYY

Nextdoor Holdings, Inc. Class A Common Stock

Nextdoor Holdings

MediaAlpha

Hello Group Inc. - American Depositary Shares

Hello Gr

QuinStreet

Shutterstock

Taboola.com

Tripadvisor

Vimeo

Vtex

Weibo Corporation - American Depositary Shares

Weibo

WEBTOON Entertainment Inc. - Common stock

Webtoon Entertainment

Yalla Group Limited American Depositary Shares, each representing one Class A Ordinary Share

Comments

FuboTV

FuboTV (FUBO) Opzioni

Loading...

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO